Influence of androgen and estrogen deprivation therapy on bone metabolism and bone mineral density in men with prostate cancer
- VernacularTitle:性激素阻断治疗对前列腺癌患者骨代谢及骨量的影响
- Author:
Song-Bai ZHENG
;
Han-Min ZHU
;
Qun CHENG
;
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Pituitary hormones;
Bone mineral density;
Osteoporosis
- From:
Chinese Journal of Geriatrics
2003;0(11):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of castration treatment by luteinizing hormonereleasing hormone(LHRH)analog(goserelin)on bone loss and bone resorption in men with prostate cancer.Methods Serum sex hormones,bone mineral density(BMD),serum and urine concentrations of bone turnover markers were determined in men with prostate cancer(n=36) and in age-matched controls(n=13).BMD in the lumbar spine(L2-4),femoral neck,trochanter,Ward's triangle and total femoral was determined by dual energy X-ray absorptiometry(DEXA).Results After 12 months of LHTH analog therapy,the BMD of the femoral neck,total femoral and Ward's triangle decreased significantly in men with prostate cancer compared with the controls,all P＜0.05. No significant bone loss was observed in the control subjects.The concentrations of the serum markers of bone formation,i.e.bone alkaline phosphatase(BALP),and urine markers of bone resorption,i. e.DPD,Cros,Ca/Cr were significantly increased in patients treated with LHRH analog compared with control subjects,all P＜0.05,respectively.Conclusions These findings demonstrate that a significant increase of bone turnover and loss of bone mass in men with prostate cancer after receiving LHRH analog therapy were correlated with the decreased levels of serum androgen and estrogen,and suggest that measuring BMD by DEXA and assesing the bone turnover markers can early detect the bone loss and osteoporosit induced by goserelin castration treatment.
